News | August 03, 2024
AbbVie completes acquisition of Cerevel Therapeutics
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Strong topline growth driven by solid performance across key brands.
Dr. Agarwals Eye Hospital has reported total income of Rs. 100.42 crores during the period ended June 30, 2024
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Subscribe To Our Newsletter & Stay Updated
